Ebola Zaire GP
Description
Ebola Zaire GP is purified by a proprietary chromatographic technique.
Product Specs
Product Science Overview
The Ebola virus, a member of the Filoviridae family, is known for causing severe hemorrhagic fever in humans and nonhuman primates. Among the various species of the Ebola virus, the Zaire ebolavirus (EBOV) is the most virulent and has been responsible for the majority of Ebola outbreaks. The glycoprotein (GP) of the Zaire ebolavirus plays a crucial role in the virus’s ability to infect host cells and is a key target for vaccine development.
The Ebola Zaire glycoprotein is a trimeric protein that is essential for the virus’s entry into host cells. It is composed of two subunits, GP1 and GP2, which are derived from a single precursor protein through proteolytic cleavage. GP1 is responsible for binding to the host cell receptor, while GP2 facilitates the fusion of the viral and host cell membranes, allowing the viral RNA to enter the host cell cytoplasm.
Recombinant glycoproteins are produced using genetic engineering techniques to express the glycoprotein in a host system, such as bacteria, yeast, or mammalian cells. The recombinant Ebola Zaire glycoprotein is typically produced in mammalian cells to ensure proper folding and post-translational modifications, which are critical for its immunogenicity and functionality.
The recombinant Ebola Zaire glycoprotein has been a focal point in the development of vaccines against Ebola virus disease. One of the most notable vaccines is the rVSV-ZEBOV, which uses a recombinant vesicular stomatitis virus (VSV) as a vector to express the Ebola Zaire glycoprotein. This vaccine has shown promising results in clinical trials, demonstrating high efficacy in preventing Ebola virus disease .
Clinical trials of the rVSV-ZEBOV vaccine have been conducted in various regions, including West Africa, where Ebola outbreaks have occurred. The vaccine has been shown to induce a strong immune response, with high levels of neutralizing antibodies against the Ebola Zaire glycoprotein. In a randomized trial, the vaccine demonstrated 100% efficacy in preventing Ebola virus disease in vaccinated individuals .
